Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

por Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortes, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Bachelot, Thomas, Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Schwartz, Gary N., Pluard, Timothy J., Ricci, Francesco, Gwin, William R., Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Gal-Yam, Einav Nili, Yerushalmi, Rinat, Fasching, Peter A., Kaufman, Peter A., Ashley, Emily J., Perez-Olle, Raul, Hong, Shengyan, Rosales, Minori Koshiji, Gradishar, William J.
Publicado 2023